22.5 Mg Leuproide Acetate Injection

Name: 22.5 Mg Leuproide Acetate Injection
Brand: NEETCO BIOPHARMA
Price: 9700 INR
Availability: InStock

Price 9700 INR/ Piece

Get a Price/Quote

MOQ : 1 Piece

22.5 Mg Leuproide Acetate Injection Specification

Dosage Form
Injection

Indication
Treatment of prostate cancer, breast cancer, endometriosis, uterine fibroids, early puberty

Salt Composition
Leuproide Acetate 22.5 mg

Feature
Long-acting formulation for sustained release

Ingredients
Leuproide Acetate, sterile water for injection, excipients

Application
Administered intramuscularly as prescribed by physician

Ph Level
Neutral (approx. pH 7.0)

Physical Color/Texture
White to off-white lyophilized powder

Fermentation Smell
Odorless

Storage Instructions
Store below 25C; protect from light; do not freeze

Shelf Life
24 months

Release Duration
Designed for 3-month sustained therapy

Contraindications
Hypersensitivity to leuproide acetate or excipients

Route of Administration
Intramuscular

Adverse Effects
Hot flashes, injection site reactions, headache, mood changes

Strength
22.5 mg per vial

Prescription Required
Yes

Regulatory Status
Approved under relevant pharmaceutical standards

Packing Type
Vial with sterile solvent for reconstitution

Reconstitution Instructions
Follow physician or pharmacy guidelines

About 22.5 Mg Leuproide Acetate Injection

Presenting the redoubtable 22.5 Mg Leuproide Acetate Injection, a magnificent solution for sustained cancer and hormone therapy. Featured by its soaring long-acting release, patients benefit from instant savings in dosage frequency. Formulated with high-value Leuproide Acetate (22.5 mg/vial), this injection is administered intramuscularly and offered in a sterile vial with solvent for secure reconstitution. Approved under stringent pharmaceutical standards, it offers a neutral pH, odorless profile, and outstanding shelf life of 24 months, underscoring reliability for distributor, exporter, supplier, and trader networks across India.

Magnificent Features and Competitive Advantages

This injection showcases a long-acting formulation designed for three-month sustained therapy, drastically reducing administration needs and offering extra convenience. Its neutral pH and odorless lyophilized powder enhance patient safety, while stringent regulatory standards and a soaring shelf life strengthen its supplier value. The product's competitive advantage lies in instant savings from reduced frequency and steadfast efficacy against prostate cancer, breast cancer, endometriosis, and more, setting it apart for healthcare professionals and distributors.

Sample Policy and Domestic Market Valuation

Sample availability for the 22.5 Mg Leuproide Acetate Injection is conditional and may entail a nominal charge for evaluation, ensuring transparent valuation processes. Samples are handed over to authentic medical professionals or distributors upon request, in compliance with local regulations. The product flourishes within the soaring domestic market in India, serving a network of trusted distributors, retailers, and medical facilities, and upholding rigorous standards throughout handling and distribution.

FAQ's of 22.5 Mg Leuproide Acetate Injection:

Q: How is the 22.5 Mg Leuproide Acetate Injection administered?

A: The injection is administered intramuscularly after reconstitution with sterile solvent, following a physician's precise instructions and pharmacy guidelines to ensure efficacy and safety.

Q: What are the main indications for using this injection?

A: It is indicated for the treatment of prostate cancer, breast cancer, endometriosis, uterine fibroids, and early puberty, providing sustained hormone modulation over a three-month release period.

Q: When should patients avoid this medication?

A: Patients with known hypersensitivity to leuproide acetate or its excipients should not use this product, as contraindications may result in adverse reactions.

Q: Where should the 22.5 Mg Leuproide Acetate Injection be stored?

A: The vials must be stored below 25C, protected from light, and should never be frozen in order to maintain product integrity and efficacy.

Q: What are the potential adverse effects of this injection?

A: Common adverse effects may include hot flashes, injection site reactions, headache, and mood changes. Patients should discuss these with the prescribing physician.

Q: What competitive advantage does this product offer distributors and suppliers?

A: The long-acting three-month release formulation reduces dosage frequency and storage needs, offering distributors instant savings, value, and a magnificent advantage over short-acting alternatives.

Tell us about your requirement